Publication Name	World Journal of Gastroenterology
Manuscript ID	85577
Country	China

Received	2023-05-04 17:05
Peer-Review Started	2023-05-04 17:08
To Make the First Decision
Return for Revision	2023-05-19 01:38
Revised	2023-05-29 13:33
Second Decision	2023-06-13 03:01
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2023-06-13 08:13
Articles in Press	2023-06-13 08:13
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2023-06-27 08:36
Publish the Manuscript Online	2023-07-10 08:58

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Progress in immunotherapy for neuroendocrine neoplasm of the digestive system
Manuscript Source	Unsolicited Manuscript
All Author List	Wei-Xuan Pan, Xin-Mu Zhang, Shao-Long Hao and Wei Han
Funding Agency and Grant Number
Corresponding Author	Wei Han, MD, Chief Doctor, Director, Professor, Department of General Surgery, Beijing Luhe Hospital, No. 28 South Xinhua Road, Tongzhou District, Beijing 101100, China. dr-han1972@mail.ccmu.edu.cn
Key Words	Immunotherapy; PD-1 inhibitor; Neuroendocrine neoplasm; Neuroendocrine tumor; Neuroendocrine carcinoma; Gastrointestinal; Pancreatic
Core Tip	The application of immune checkpoint inhibitor (ICI) in neuroendocrine neoplasm (NEN) is regulated by the latest clinical practice guidelines. However, immunotherapy has achieved some breakthroughs for high-grade or advanced NENs of the digestive system, for which there is currently no effective drug therapy. In this regard, we investigated the causes of the heterogeneous efficacy of ICI in NEN with different grades, differentiation, and primary organs. This review summarizes the state-of-the-art progress and trend of clinical trials for different ICI-containing regimens in NENs of the digestive system, which will aid in the conduct of subsequent clinical trials and research of related mechanisms.
Publish Date	2023-07-10 08:58
Citation	Pan WX, Zhang XM, Hao SL, Han W. Progress in immunotherapy for neuroendocrine neoplasm of the digestive system. World J Gastroenterol 2023; 29(26): 4174-4185
URL	https://www.wjgnet.com/1007-9327/full/v29/i26/4174.htm
DOI	https://dx.doi.org/10.3748/wjg.v29.i26.4174

Full Article (PDF)	WJG-29-4174-with-cover.pdf
Full Article (Word)	WJG-29-4174.docx
Manuscript File	85577_Auto_Edited-LJH-JLW.docx
Answering Reviewers	85577-Answering reviewers.pdf
Audio Core Tip	85577-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	85577-Conflict-of-interest statement.pdf
Copyright License Agreement	85577-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	85577-Grant application form(s).pdf
Non-Native Speakers of English Editing Certificate	85577-Language certificate.pdf
Peer-review Report	85577-Peer-review(s).pdf
Scientific Misconduct Check	85577-Bing-Liu JH-2.png
Scientific Misconduct Check	85577-CrossCheck.png
Scientific Editor Work List	85577-Scientific editor work list.pdf